Portal de Periódicos da CAPES

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

2012; Massachusetts Medical Society; Volume: 366; Issue: 3 Linguagem: Inglês

10.1056/nejmoa1105358

1533-4406

Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais,

PI3K/AKT/mTOR signaling in cancer

Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.